Search
Aligos Therapeutics Inc
ALGSAdd to Watchlist
6.710USD
-0.180-2.61%
Market hours （ET）Quotes delayed by 15 min
41.85MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Aligos Therapeutics Inc is 8.25, ranking 149 out of 387 in the Biotechnology & Medical Research industry. The average price target is 55.00, with a high of 175.00 and a low of 36.00.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
54.875
Target Price
+696.44%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Aligos Therapeutics Inc
ALGS
8
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Aligos Therapeutics Inc's expected revenue for the next quarter?
Aligos Therapeutics Inc's expected revenue is 1.11M.
What is Aligos Therapeutics Inc's price target?
Analysts forecast that Aligos Therapeutics Inc's price target is USD 55.00, with the highest forecast at USD 175.00 and the lowest forecast at USD 36.00.
How have Aligos Therapeutics IncALGS's recent earnings per share performed?
The market expectation was USD -0.14, while Aligos Therapeutics IncALGS's earnings per share (EPS) for the previous quarter was USD -2.21. EPS for the next quarter is expected at USD -2.16.
What is the analyst rating for Aligos Therapeutics Inc?
Based on the ratings of Aligos Therapeutics Inc's stock from 8 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.